Notable Labs, Ltd. · OTC:NTBLQ
Notable Labs — Merger or Acquisition (February 2023)
25 slides from Notable Labs's merger presentation, Feb 23, 2023
Slide 1: VBL Therapeutics Proposed Merger With Notable Labs
VBL Therapeutics Proposed Merger With Notable Labs February 23, 2023
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure
Slide 3: Additional Information About the Proposed Merger
Additional Information About the Proposed Merger Additional Information About the Proposed Merger and Where to Find It This communication relates to the proposed merger transaction involving Vascular Biogenics, Ltd. (doing business as VBL Therapeutics) and Notable Labs and may be deemed to be solici
Slide 4: Proposed Notable Labs & VBL Therapeutics Merger
Proposed Notable Labs & VBL Therapeutics Merger • Follows VBL Therapeutics extensive review of strategic alternatives • All-stock transaction: VBL Therapeutics to acquire all outstanding shares of Notable Labs in exchange for newly issued ordinary shares of VBL Therapeutics • Notable Labs stockholde
Slide 5: Defining predictive precision medicine
Defining predictive precision medicine, we aim to dramatically improve patient outcomes and the success, speed and ROI on drug development.
Slide 6: Traditional Precision Medicines Are Limited
Traditional Precision Medicines Are Limited Patients Urgently Need Approaches Going Beyond Genetic Mutations Less than 15% of cancer patients1 carry a known actionable genetic marker, and thus can benefit from traditional precision medicines In many clinical settings, traditional precision medicines
Slide 7: Predicting Clinical Response and De-Risking Drug Development
Predicting Clinical Response With a Goal of Improving Patient Outcomes and De-Risking Drug Development Predictive Precision Medicine Platform, PPMP Business Model Biology & Technology Validated & Scalable From Shelf to Leadership Assets in Development Volasertib • Reliably identifies patients most •
Slide 8: Predictive Precision Medicine Platform (PPMP)
Predictive Precision Medicine Platform (PPMP) Designed to Predict Patient Response Within Clinically Actionable Timeframe Patient PPMP Predicted Actual Sample Platform Responders Responders Patient Treat Response Predictor Add Drug or Drug Combination Predicted Non-Responder Predictive Precision tra
Slide 9: PPMP Merges Biology and Technology
PPMP Merges Biology and Technology Designed to Overcome the Limitations of Traditional Precision Medicines and AI- Driven Drug Design Biology Technology Replaces one-dimensional targeting with Puts biology back multi-dimensional response measuring into computational models 9
Slide 10: Superior Differentiation of Notable's Business Model
Superior Differentiation of Notable’s Business Model Target the most compelling assets available using PPMP Fast-track remaining development selectively in responding patients with smaller and less costly trials Deliver a superior competitive profile and new patent life (platform + product) 10
Slide 11: We Aspire to Dramatically Improve Outcomes for Patients – Predictably
We Aspire to Dramatically Improve Outcomes for Patients – Predictably Medical Practice Today Notable Labs Vision ? ! Chose between treatments with less than 30% response rate Simply test first and selectively based on complex literature/guidelines treat predicted responders 100 100 80 80 60 60 40 40
Slide 12: Improved Patient Outcomes, De-Risked Drug Development
Notable’s Target Impact • Higher Market Penetration Improved • Benefits for Payers Patient Outcomes • Optimized Drug Combinations Predict & Select Responding • New Patent Life Patients • Smaller Trials De-Risked • Faster Trials Drug Development • Lower Cost 12
Slide 13: Predictive Precision Medicines Pipeline
Predictive Precision Medicines Pipeline Lead indications target high unmet medical needs Asset Indication Preclinical Phase 1 Phase 2 Phase 3 Development Rights Volasertib AML Fosciclopirox AML 13
Slide 14: Notable's Platform Merges Biology & Technology
Notable’s Predictive Precision Medicine Platform Merges Biology & Technology Fresh Cytokines/ Growth Factors Multiple Readouts patient sample at the Single Cell Level Media Stromal Components Components Live Cancer Dying (Apoptosis) + Immune cells MICROENVIRONMENT Dead PARAMETERS Proliferating Assay
Slide 15: Notable Has Created A Massive Data Repository
Differentiation: Notable Has Created A Massive Data Repository Massive existing cell function 190 billion Notable receives up to 10% of a dataset in hematology lines of data given day’s AML patients in the U.S. 9,000 Other Ovarian 8,000 APL Cumulative Number of Samples 7,000 Lymphoma MCL 6,000 CMML
Slide 16: Notable's Clinical Validation Studies
Notable’s Clinical Validation Studies Adult Patients With Either 54 Unique HR-MDS Patients 10 Adult AML Patients 20 De Novo Pediatric AML Patients MDS or AML Standard-Of-Care Treatment Patients Screened Against 74 Standard-Of-Care Treatment Standard-Of-Care ADE (Cytarabine+Idarubicin or Compounds an
Slide 17: PPMP Has Demonstrated 83-100% Predictive Precision
PPMP Has Demonstrated 83-100% Predictive Precision In three clinical validation studies with world-class medical centers HR-MDS and AML R/R AML Pediatric AML Washington University To be presented at AACR in April 2023 Patient Response in the Real World Predictive Precision 100% 83% 100% Across three
Slide 18: Predictive Precision Translates Into Clinical Response Rate
Predictive Precision Translates Into Clinical Response Rate Predictive Precision is defined as how many PPMP-predicted responders achieved a clinical response in the real world Texas Clinical Stanford MD Anderson Washington Children’s Validation University Cancer Center University Hospital (TCH) TCH
Slide 19: Volasertib Was Identified Using a PPMP-Driven Search
Volasertib was Identified Using a PPMP-Driven Search for High-Value Assets Demonstrated Outstanding Clinical Activity & Platform Volasertib Tolerability Performance • Demonstrated clinical activity signal in • Quickly move to MTA to procure • Compelling clinical activity in a subset defined populati
Slide 20: Volasertib Response Rate in Notable's Avatar Trial
Volasertib Response Rate in Notable’s Avatar Trial Matched Boehringer Ingelheim’s Phase 2/3 Response Rate Patient population for upcoming Volasertib prospective trial Results: 30% Predicted • 30% (20/65) of patients demonstrated ex Responders vivo response • Avatar response rate = Phase 2 & 3 clinic
Slide 21: Development Strategy Designed to Reduce Patient Numbers, Time and Cost
Development Strategy Designed to Reduce Patient Numbers, Time and Cost 75% fewer patients vs. traditional trials FDA-Approved Phase 2a Phase 2b NDA 30 Patients 20 Patients Pivotal Registration Trial Therapeutic (selected population) (non-selected) (selected) Decide Decide FDA-Approved Score Phase 3
Slide 22: Volasertib and Fosciclopirox Development Plans
Volasertib and Fosciclopirox Development Plans: Notable anticipates delivering multiple near-term value-inflection milestones Date Drug + PPMP Description 2Q 2023 PPMP Fourth Clinical Validation Study at AACR 3Q 2023 Volasertib Phase 2A Trial Initiation in Adult AML Phase 2A Topline Results Readout
Slide 23: Experienced Management Team
Experienced Management Team Notable’s management integrate expertise and innovation across therapeutics, diagnostics and engineering Key Investors Thomas Bock Joseph Wagner Matt De Silva MD, MBA PhD Vice President, Chief Executive Chief Scientific & Founder, Engineering Officer Chief Executive Offic
Slide 24: Our Vision: Transform Patient Outcomes Through Predictive Precision Medicines
Our Vision: Transform Patient Outcomes Through Predictive Precision Medicines Patient by Patient, Cancer by Cancer Biology + Validated + From Shelf to Fast-Paced Technology Scalable Leadership Value Inflection 24
Slide 25: Thank You
Thank You